Efficacy and Safety of Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis.

Autor: Lebel E; Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.; Department of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Asherie N; Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Kfir-Erenfeld S; Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Grisariu S; Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Avni B; Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Elias S; Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Assayag M; Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Dubnikov-Sharon T; Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Pick M; Department of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Alexander-Shani R; Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Bessig N; Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Herr S; Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Shehadeh A; Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Ishtay A; Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Pimienta S; Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Vainstein V; Department of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Zimran E; Department of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Cohen Y; Department of Hematology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Avivi I; Department of Hematology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Cohen C; Laboratory of Tumor Immunology and Immunotherapy, The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel., Stepensky P; Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Gatt ME; Department of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Dec 09, pp. JCO2402252. Date of Electronic Publication: 2024 Dec 09.

Belantamab Mafodotin in Relapsed/Refractory AL Amyloidosis: Real-World Multi-Center Experience and Review of the Literature.

Autor: Lebel E; Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.; Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel., Vainstein V; Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.; Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel., Milani P; Department of Molecular Medicine, University of Pavia, Pavia, Italy.; Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Palladini G; Department of Molecular Medicine, University of Pavia, Pavia, Italy.; Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Shragai T; Department of Hematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel., Lavi N; Department of Hematology, Rambam Health Care Campus, Haifa, Israel., Magen H; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.; Department of Hematology, Chaim Sheba Medical Center, Ramat-Gan, Israel., Assayag M; Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.; Bone Marrow Transplant and Cellular Therapy Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel., Avivi I; Department of Hematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel., Gatt ME; Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.; Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Publikováno v: Acta haematologica [Acta Haematol] 2024 Oct 02, pp. 1-8. Date of Electronic Publication: 2024 Oct 02.

The integrin receptor beta 7 subunit mediates airway remodeling and hyperresponsiveness in allergen exposed mice.

Autor: Assayag M; Department of Pulmonary Medicine, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Ein Kerem, Jerusalem, Israel., Obedeyah T; Department of Pulmonary Medicine, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Ein Kerem, Jerusalem, Israel., Abutbul A; Department of Pulmonary Medicine, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Ein Kerem, Jerusalem, Israel., Berkman N; Department of Pulmonary Medicine, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Ein Kerem, Jerusalem, Israel. Neville@hadassah.org.il.

Publikováno v: Respiratory research [Respir Res] 2024 Jul 12; Vol. 25 (1), pp. 273. Date of Electronic Publication: 2024 Jul 12.

Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma.

Autor: Gagelmann N; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Dima D; Cleveland Clinic Taussig Cancer Center, Cleveland, OH.; US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS., Merz M; Department of Hematology, Cellular Therapy, Hemostaseology and Infectiology, University Hospital of Leipzig, Leipzig, Germany., Hashmi H; US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS.; Medical University of South Carolina, Charleston, SC., Ahmed N; US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS.; The University of Kansas Medical Center, Kansas City, KS., Tovar N; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Oliver-Caldés A; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Stölzel F; Division for Stem Cell Transplantation and Cellular Immunotherapy, Department of Medicine II, University Hospital Schleswig-Holstein Kiel, Kiel University, Kiel, Germany., Rathje K; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Fischer L; Department of Hematology, Cellular Therapy, Hemostaseology and Infectiology, University Hospital of Leipzig, Leipzig, Germany., Born P; Department of Hematology, Cellular Therapy, Hemostaseology and Infectiology, University Hospital of Leipzig, Leipzig, Germany., Schäfer L; Department of Hematology and Medical Oncology, Medical Center University of Göttingen, Göttingen, Germany., Albici AM; Division for Stem Cell Transplantation and Cellular Immunotherapy, Department of Medicine II, University Hospital Schleswig-Holstein Kiel, Kiel University, Kiel, Germany., Schub N; Division for Stem Cell Transplantation and Cellular Immunotherapy, Department of Medicine II, University Hospital Schleswig-Holstein Kiel, Kiel University, Kiel, Germany., Kfir-Erenfeld S; Department of Bone Marrow Transplantation and Cancer Immunotherapy, Faculty of Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel., Assayag M; Department of Bone Marrow Transplantation and Cancer Immunotherapy, Faculty of Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel., Asherie N; Department of Bone Marrow Transplantation and Cancer Immunotherapy, Faculty of Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel., Wulf GG; Department of Hematology and Medical Oncology, Medical Center University of Göttingen, Göttingen, Germany., Kharboutli S; Department of Internal Medicine, Haematology and Oncology, University Hospital of Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg (FAU), Erlangen, Germany., Müller F; Department of Internal Medicine, Haematology and Oncology, University Hospital of Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg (FAU), Erlangen, Germany., Shune L; US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS.; The University of Kansas Medical Center, Kansas City, KS., Davis JA; US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS.; Medical University of South Carolina, Charleston, SC., Anwer F; Cleveland Clinic Taussig Cancer Center, Cleveland, OH.; US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS., Vucinic V; Department of Hematology, Cellular Therapy, Hemostaseology and Infectiology, University Hospital of Leipzig, Leipzig, Germany., Platzbecker U; Department of Hematology, Cellular Therapy, Hemostaseology and Infectiology, University Hospital of Leipzig, Leipzig, Germany., Ayuk F; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Kröger N; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Khouri J; Cleveland Clinic Taussig Cancer Center, Cleveland, OH., Gurnari C; Cleveland Clinic Taussig Cancer Center, Cleveland, OH.; Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Rome, Italy., McGuirk J; US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS.; The University of Kansas Medical Center, Kansas City, KS., Stepensky P; Department of Bone Marrow Transplantation and Cancer Immunotherapy, Faculty of Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel., Abdallah AO; US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS.; The University of Kansas Medical Center, Kansas City, KS., Fernández de Larrea C; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 May 10; Vol. 42 (14), pp. 1665-1675. Date of Electronic Publication: 2024 Feb 15.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.